Skip to main content
Vericel Corp logo

Vericel Corp — Investor Relations & Filings

Ticker · VCEL ISIN · US92346J1088 LEI · 54930076YM3PLTDR4B91 US Manufacturing
Open in API
Filings indexed 1,130 across all filing types
Latest filing 2012-10-04 Board/Management Inform…
Country US United States of America
Listing US VCEL

About Vericel Corp

https://vcel.com/

Vericel Corporation is a biopharmaceutical company that develops, manufactures, and commercializes advanced cell therapies for the sports medicine and severe burn care markets. The company's portfolio is centered on autologous (patient-specific) cell-based products. Key commercial products include MACI® (autologous cultured chondrocytes on porcine collagen membrane), a tissue-engineered product for the repair of symptomatic cartilage defects of the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for patients with severe burns. Additionally, Vericel holds the exclusive North American commercial rights for NexoBrid®, a biological orphan product used for the removal of eschar in adults with deep partial-thickness or full-thickness thermal burns.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 4, 2012. The key content is the announcement of the retirement of the company's President and CEO and the appointment of a new chairman of the Board of Directors. This is a clear announcement of changes in the company's board and senior management. There are no financial statements or detailed financial data presented, so it is not an annual or interim report. The document is not a call transcript, earnings release, or any other type of report. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3589 characters, which is typical for an 8-K announcement of management changes.
2012-10-04 English
FORM 4 -
Director's Dealing
2012-08-30 English
8-K/A
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. The content specifically supplements information about the results of voting at the company's Annual Meeting of Stockholders, particularly regarding an advisory vote on executive compensation frequency. The document does not contain full financial statements or detailed financial analysis, but rather provides an update on shareholder voting results. This aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3629 characters, which is relatively short and focused on voting results rather than a full report or presentation. Therefore, the appropriate classification is DVA with high confidence.
2012-08-22 English
FORM 8-K FILING DOCUMENT
Earnings Release Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated August 7, 2012, for Aastrom Biosciences, Inc. It includes a press release attached as Exhibit 99.1 regarding results of operations and financial condition. The document itself is a current report announcing financial results, typical of an earnings release. The length is 2594 characters, which is short and consistent with an 8-K earnings release filing. The key section is Item 2.02, which is specifically for Results of Operations and Financial Condition, indicating an earnings release. Therefore, the document is best classified as an Earnings Release (ER).
2012-08-08 English
10-Q
Interim / Quarterly Report Q2 2012
2012-08-07 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 30, 2012. It reports on an event related to an Exchange Offer for warrants to purchase common stock. The document includes a press release as an exhibit announcing the results of the Exchange Offer. The content is an event-driven current report rather than a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the event. The nature of the filing fits the category of Capital/Financing Update (CAP), as it relates to a financing activity involving exchange of warrants for common stock.
2012-07-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.